<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Charles River Laboratories 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=50887></link><description><![CDATA[Charles River Laboratories 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 17 May 2026 12:42:47 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/05/12_31017998_20260517105153_6448442172.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[찰스 리버 래버러토리스와 메디포스트, GMP 시험 솔루션 고도화를 위한 비독점 양해각서 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1034625</link><description><![CDATA[윌밍턴, 매사추세츠--(Business Wire/뉴스와이어)--찰스 리버 래버러토리스(Charles River Laboratories, CRL)와 메디포스트(MEDIPOST Co., Ltd., 코스닥: 078160)는 GMP 준수 시험은 물론 세포치료제 개발 및 상용화 촉진을 위한 보다 광범위한 상업·마케팅 활동 분야에서 협력하기 위해 전략적 비독점 양해각서(MOU)를 체결했다. 이번 파트너십을 통해 양사는 찰스 리버가 보유한 바이오의약품 및 세포치료제 GMP 시험 분야...]]></description><pubDate>Sun, 17 May 2026 11:01:01 +0900</pubDate></item><item><title><![CDATA[Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1034624</link><description><![CDATA[WILMINGTON, Mass--(Business Wire/Korea Newswire)--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River’...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2026/05/31017998_20260517105726_4275978852.jpg]]></url></image><pubDate>Sun, 17 May 2026 11:00:39 +0900</pubDate></item></channel></rss>